| |
|
|
|
Xtalks, Online
2025-01-08
Gene therapy manufacturing is complex, resource-intensive, and time-sensitive — every day counts for developers and their patients. As the industry grows to address more diseases and broader patient populations, manufacturing must keep pace with these expanding needs.
Innovative adeno-associated virus (AAV) manufacturing platforms can help meet these challenges, offering solutions for faster, potentially safer, and more efficient AAV production.
Forge’s FUEL™ AAV manufacturing platform was designed to meet these challenges, offering innovative solutions for faster, potentially safer, and more efficient AAV production. Powered by proprietary technologies—including Forge’s new pEMBR 2.0™ Ad Helper plasmid, new modified rep/caps, and its trusted HEK293 suspension Ignition Cells™—FUEL™ can boost productivity compared to industry standard.
This webinar explores how molecular and technical innovations can enhance AAV manufacturing and highlights the impressive productivity gains that can be achieved.
Register for this webinar today to discover how innovative AAV platform manufacturing technologies are driving faster, safer and more efficient manufacturing solutions for gene therapies.
Keywords: Gene Therapy, Drug Development, Clinical Research, CRO, Gene Therapies, Cell and Gene Therapy, AAV, Cell & Gene Therapy, Cell & Gene Therapies, AAV Manufacturing, CGT
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
David Dismuke, PhD, Chief Technical Officer, Forge Biologics
Frank Agbogbo, PhD, Vice President, Process Development, Forge Biologics
Linas Padegimas, PhD, Senior Director, R&D, Forge Biologics
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-01-08
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|